Department of Biomedical Engineering, Boston University, Boston, MA 02215, United States.
J Control Release. 2010 Jun 15;144(3):280-7. doi: 10.1016/j.jconrel.2010.02.022. Epub 2010 Feb 22.
Local tumor recurrence has a major impact on long-term patient survival following the surgical treatment of most cancers, and this is especially true with lung cancer. Consequently, methods to deliver chemotherapeutics locally at a lung tumor resection margin would be beneficial since: 1) systemic treatment approaches are ineffective or highly toxic; 2) the incidence of local recurrence does not warrant universal treatment of all patients with a highly morbid systemic therapy; and 3) surgical resection of recurrent disease is not an option and alternative rescue therapies are generally unsuccessful. To begin to meet this clinical need, we have prepared poly(glycerol monostearate-co-epsilon-caprolactone) films as a controlled, prolonged, and low dose delivery matrix for the potent anticancer agent 10-hydroxycamptothecin (HCPT). These drug-loaded films were applied to a collagen-based scaffold clinically indicated for the mechanical buttressing of lung tissue following surgical resection, resulting in a flexible composite that can be secured to the tissue that releases HCPT over seven weeks and thereby prevents the local growth and establishment of Lewis lung carcinoma tumors in vivo (a freedom of local tumor growth of 86%). In comparison, all animals treated with a larger intravenous dose of HCPT or unloaded composites developed rapid local tumors.
局部肿瘤复发对大多数癌症手术后患者的长期生存有重大影响,肺癌尤其如此。因此,局部递送至肺癌切除边缘的化疗药物的方法将是有益的,因为:1)全身治疗方法无效或毒性高;2)局部复发的发生率不需要对所有患者进行高度致病变态的全身治疗;3)复发性疾病的手术切除不是一种选择,并且替代救援疗法通常不成功。为了开始满足这一临床需求,我们已经制备了聚(甘油单硬脂酸酯-co-ε-己内酯)薄膜作为一种受控的、延长的、低剂量的载体,用于强效抗癌药物 10-羟基喜树碱(HCPT)。将这些载药薄膜应用于一种基于胶原蛋白的支架上,该支架临床上用于在手术后机械支撑肺组织,形成一种柔性复合材料,可以固定在组织上,在七周内释放 HCPT,从而防止体内 Lewis 肺癌肿瘤的局部生长和建立(局部肿瘤生长的自由为 86%)。相比之下,所有接受较大剂量静脉内 HCPT 或未载药复合材料治疗的动物都迅速发生局部肿瘤。